Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab.

Carcao M, Escuriola-Ettingshausen C, Santagostino E, Oldenburg J, Liesner R, Nolan B, Bátorová A, Haya S, Young G; Future of Immunotolerance Treatment Group.

Haemophilia. 2019 Apr 29. doi: 10.1111/hae.13762. [Epub ahead of print]

PMID:
31033112
2.

Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate® ) and BAY 81-8973 (Kovaltry® ) in patients with severe or moderate haemophilia A in prophylaxis.

Megías-Vericat JE, Bonanad S, Haya S, Cid AR, Marqués MR, Monte-Boquet E, Pérez-Alenda S, Bosch P, Querol F, Poveda JL.

Haemophilia. 2019 May;25(3):e215-e218. doi: 10.1111/hae.13733. Epub 2019 Mar 13. No abstract available.

PMID:
30866068
3.

Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A.

Megías-Vericat JE, Bonanad S, Haya S, Cid AR, Marqués MR, Monte E, Pérez-Alenda S, Bosch P, Querol F, Poveda JL.

Thromb Res. 2019 Feb;174:151-162. doi: 10.1016/j.thromres.2018.12.027. Epub 2019 Jan 3.

PMID:
30634166
4.

Predictive factors of immune tolerance treatment response in severe haemophilia A patients with inhibitors: A real-world report from a single centre, mixed retrospective-prospective long-term study.

Haya S, Solano C, Cid AR, Argilés B, Hervás D, Querol F, Bonanad S, Casaña P.

Haemophilia. 2019 Mar;25(2):e97-e100. doi: 10.1111/hae.13660. Epub 2019 Jan 3. No abstract available.

PMID:
30604912
5.

Allogeneic hematopoietic cell transplantation in an adult patient with Glanzmann thrombasthenia.

Cid AR, Montesinos P, Sánchez-Guiu I, Haya S, Lorenzo JI, Sanz J, Moscardo F, Puig N, Planelles D, Bonanad S, Sanz GF, Vicente V, González-Manchón C, Lozano ML, Rivera J, Sanz MA.

Clin Case Rep. 2017 Oct 5;5(11):1887-1890. doi: 10.1002/ccr3.1206. eCollection 2017 Nov.

6.

Mortality caused by intracranial bleeding in non-severe hemophilia A patients.

Loomans JI, Eckhardt CL, Reitter-Pfoertner SE, Holmström M, van Gorkom BL, Leebeek FWG, Santoro C, Haya S, Meijer K, Nijziel MR, van der Bom JG, Fijnvandraat K.

J Thromb Haemost. 2017 Jun;15(6):1115-1122. doi: 10.1111/jth.13693. Epub 2017 May 4.

7.

Variation in baseline factor VIII concentration in a retrospective cohort of mild/moderate hemophilia A patients carrying identical F8 mutations.

Loomans JI, van Velzen AS, Eckhardt CL, Peters M, Mäkipernaa A, Holmstrom M, Brons PP, Dors N, Haya S, Voorberg J, van der Bom JG, Fijnvandraat K.

J Thromb Haemost. 2017 Feb;15(2):246-254. doi: 10.1111/jth.13581. Epub 2017 Feb 3.

8.

Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.

Eckhardt CL, van Velzen AS, Peters M, Astermark J, Brons PP, Castaman G, Cnossen MH, Dors N, Escuriola-Ettingshausen C, Hamulyak K, Hart DP, Hay CR, Haya S, van Heerde WL, Hermans C, Holmström M, Jimenez-Yuste V, Keenan RD, Klamroth R, Laros-van Gorkom BA, Leebeek FW, Liesner R, Mäkipernaa A, Male C, Mauser-Bunschoten E, Mazzucconi MG, McRae S, Meijer K, Mitchell M, Morfini M, Nijziel M, Oldenburg J, Peerlinck K, Petrini P, Platokouki H, Reitter-Pfoertner SE, Santagostino E, Schinco P, Smiers FJ, Siegmund B, Tagliaferri A, Yee TT, Kamphuisen PW, van der Bom JG, Fijnvandraat K; INSIGHT Study Group.

Blood. 2013 Sep 12;122(11):1954-62. doi: 10.1182/blood-2013-02-483263. Epub 2013 Aug 7. Erratum in: Blood. 2014 May 8;123(19):3056.

9.

Efficacy of factor IX Grifols(®) in surgery: experience of an international multicentre retrospective study.

Pérez-Garrido R, Alonso N, Jiménez-Yuste V, Haya S, Zúñiga P, Baques A, Candela M, Dávoli M, Rescia V.

Haemophilia. 2012 Sep;18(5):e372-3. doi: 10.1111/j.1365-2516.2012.02919.x. Epub 2012 Jul 30. No abstract available.

PMID:
22845857
10.

Large deletion in the Factor VIII gene (F8) involving segmental duplications in int22h shows no haematological phenotype in female carriers, but may be embryonic lethal in males.

Casaña P, Mayo S, Monfort S, Orellana C, Haya S, Cid AR, Roselló M, Oltra S, Martínez F.

Br J Haematol. 2012 Jul;158(1):138-40. doi: 10.1111/j.1365-2141.2012.09092.x. Epub 2012 Mar 19. No abstract available.

PMID:
22429151
11.

Ultrasonography in the monitoring of management of haemarthrosis.

Aznar JA, Abad-Franch L, Perez-Alenda S, Haya S, Cid AR, Querol F.

Haemophilia. 2011 Sep;17(5):826-8. doi: 10.1111/j.1365-2516.2011.02538.x. Epub 2011 Apr 19. No abstract available.

PMID:
21501338
12.

Characterization of lateral flagella of Selenomonas ruminantium.

Haya S, Tokumaru Y, Abe N, Kaneko J, Aizawa S.

Appl Environ Microbiol. 2011 Apr;77(8):2799-802. doi: 10.1128/AEM.00286-11. Epub 2011 Feb 18.

13.

Identification of deletion carriers in hemophilia B: quantitative real-time polymerase chain reaction or multiple ligation probe amplification.

Casaña P, Haya S, Cid AR, Oltra S, Martínez F, Cabrera N, Aznar JA.

Transl Res. 2009 Mar;153(3):114-7. doi: 10.1016/j.trsl.2008.12.006. Epub 2009 Jan 27.

PMID:
19218093
14.
15.

Novel missense mutation c.2685G>C (p.Q895H) in VWF gene associated with very low levels of VWF mRNA.

Cabrera N, Casaña P, Cid AR, Haya S, Moret A, Aznar JA.

Ann Hematol. 2009 Mar;88(3):245-7. doi: 10.1007/s00277-008-0576-7. Epub 2008 Aug 20.

PMID:
18712522
16.

One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype.

Cid AR, Calabuig M, Cortina V, Casaña P, Haya S, Moret A, Cabrera N, Aznar JA.

Haemophilia. 2008 Sep;14(5):1049-54. doi: 10.1111/j.1365-2516.2008.01781.x. Epub 2008 Jun 5.

PMID:
18540892
17.

Severe and moderate hemophilia A: identification of 38 new genetic alterations.

Casaña P, Cabrera N, Cid AR, Haya S, Beneyto M, Espinós C, Cortina V, Dasí MA, Aznar JA.

Haematologica. 2008 Jul;93(7):1091-4. doi: 10.3324/haematol.12344. Epub 2008 Apr 9.

18.

Inhibitors in haemophilia A: current management and open issues.

Haya S, Moret A, Cid AR, Cortina V, Casaña P, Cabrera N, Aznar JA.

Haemophilia. 2007 Dec;13 Suppl 5:52-60. doi: 10.1111/j.1365-2516.2007.01574.x. Review.

PMID:
18078398
19.

Treatment in a haemophiliac A patient with paroxysmal atrial fibrillation and ischemic heart disease.

Cid AR, Zorio E, Haya S, Zúñiga P, Rueda J, Casaña P, Cabrera N, Arnau MA, Aznar JA.

Haemophilia. 2007 Nov;13(6):760-2. No abstract available.

PMID:
17973853
20.

European study on orthopaedic status of haemophilia patients with inhibitors.

Morfini M, Haya S, Tagariello G, Pollmann H, Quintana M, Siegmund B, Stieltjes N, Dolan G, Tusell J.

Haemophilia. 2007 Sep;13(5):606-12.

PMID:
17880451
21.

Inhibitor development in one patient and laboratory discrepancies in several families with both mild haemophilia and Arg531Cys mutation.

Cid AR, Casaña P, Cabrera N, Haya S, Cortina V, Aznar JA.

Haemophilia. 2007 Mar;13(2):206-8.

PMID:
17286776
22.
23.

Molecular analyses in hemophilia B families: identification of six new mutations in the factor IX gene.

Espinós C, Casaña P, Haya S, Cid AR, Aznar JA.

Haematologica. 2003 Feb;88(2):235-6. No abstract available.

24.

Orthoses in haemophilia.

Querol F, Aznar JA, Haya S, Cid A.

Haemophilia. 2002 May;8(3):407-12. Review.

PMID:
12010442
25.

Significant linkage and non-linkage of type 1 von Willebrand disease to the von Willebrand factor gene.

Casaña P, Martínez F, Haya S, Espinós C, Aznar JA.

Br J Haematol. 2001 Dec;115(3):692-700.

PMID:
11736956
26.

Association of the 3467C>T mutation (T1156M) in the von Willebrand's factor gene with dominant type 1 von Willebrand's disease.

Casaña P, Martínez F, Haya S, Espinós C, Aznar JA.

Ann Hematol. 2001 Jul;80(7):381-3.

PMID:
11529461
27.
28.

Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry.

Haya S, López MF, Aznar JA, Batlle J; Spanish Immune Tolerance Group.

Haemophilia. 2001 Mar;7(2):154-9.

PMID:
11260274
29.

A comparison of FVII:C and FVIIa assays for the monitoring of recombinant factor VIIa treatment.

Cid AR, Lorenzo JI, Haya S, Montoro JM, Casaña P, Aznar JA.

Haemophilia. 2001 Jan;7(1):39-41.

PMID:
11136379
30.

Q1311X: a novel nonsense mutation of putative ancient origin in the von Willebrand factor gene.

Casaña P, Martínez F, Haya S, Lorenzo JI, Espinós C, Aznar JA.

Br J Haematol. 2000 Nov;111(2):552-5.

PMID:
11122100
31.

Identification of a new candidate mutation, G1629R, in a family with type 2A von Willebrand disease.

Casaña P, Martínez F, Haya S, Aznar JA.

Am J Hematol. 1999 Apr;60(4):309-10.

32.

Development of a factor VIII inhibitor in a newborn haemophiliac.

Haya S, Lorenzo JI, Dasí MA, Aznar JA.

Haemophilia. 1998 Sep;4(5):755-6.

PMID:
9873883
34.
35.

[Seroprevalence of hepatitis A in hemophiliacs].

Molina R, Lorenzo JI, Gómez MD, Sarrión A, Haya S, Querol F, Aznar JA.

Sangre (Barc). 1996 Oct;41(5):363-5. Spanish.

PMID:
9026922
36.

[3 families with a congenital factor X deficiency, one of them with an associated factor XII deficiency].

Pérez Sánchez M, López J, López JL, Haya S, Lavilla E, Cárdenas MC, Rey L, Gómez N, Fernández-Rañada JM.

Sangre (Barc). 1993 Feb;38(1):57-61. Spanish.

PMID:
8470037
37.

ABO incompatible bone marrow transplants: comparison of the three methods used at the Hospital de la Princesa.

Lamana M, Perez M, Otero MJ, Haya S, Pons MJ, Fernandez Villalta MJ, Fernandez-Rañada JM.

Prog Clin Biol Res. 1992;377:333-6. No abstract available.

PMID:
1279711

Supplemental Content

Support Center